SARS-CoV Specific Neutra™ Antibody Products
Product listDo you encounter lengthy drug development timelines or face obstacles in both antibody development and creating viral infection treatments? Creative Biolabs' SARS-CoV Specific Neutra™ Antibody Products expedite your progress with advanced protein engineering methods and precise antibody development.
Overview of SARS-CoV
The genome of severe acute respiratory syndrome-related coronavirus (SARS-CoV) contains single-stranded RNA, which functions as a positive-sense virus, allowing it to evolve and adapt through time. The SARS-CoV belongs to the Coronaviridae family and leads to severe respiratory diseases among humans. Historically, SARS-CoV showed the ability of coronaviruses to cross species boundaries and produce substantial global health crises.
Structure
SARS-CoV virons appear as spherical, enveloped particles. Diameter is 80-120 nm. Key structural proteins include:
- Spike (S) protein: Facilitates receptor attachment and membrane fusion, serving as the primary focus for neutralizing antibodies.
- Envelope (E) protein: Participates in the assembly and release of virions.
- Membrane (M) protein: M protein functions as the most common structural protein critical for assembling the virion.
- Nucleocapsid (N) protein: Encloses the viral RNA genome.
Fig. 1 Schmatic diagram of the structural organization of SARS-CoV-2.1, 3
Related Signaling Pathways
SARS-CoV infection activates complex host cell signaling networks. Researching these pathways provides essential insights that lead to the creation of successful therapeutic strategies. The key pathways involved include:
- Interferon (IFN) response: The virus has the ability to either evade or suppress the production of IFN as part of the host's innate immune response.
- NF-κB pathway: When this pathway becomes active, it triggers inflammation and a large secretion of cytokines during severe cases.
- MAPK pathways: Depending the viral replication cycle and programmed cell death in host cells.
Fig. 2 Various disrupted pathways in the context of COVID-19.2, 3
Related Diseases
The virus is responsible for severe acute respiratory syndrome (SARS), characterized by symptoms such as elevated fever, persistent cough, difficulty breathing, and pneumonia. In serious instances of ARDS affects the lungs. The 2002-2003 SARS epidemic caused widespread global consequences due to its high fatality rate.
Utilization of Anti-SARS-CoV Antibody
Therapeutic Intervention
Research has focused on anti-SARS-CoV antibodies, including neutralizing monoclonal antibodies for therapeutic SARS treatment. These antibodies work by directly attacking the virus to block its entry into host cells and stop replication. Then, block the binding of the viral S protein to the ACE2 receptor on host cells, which helps decrease viral load and reduces disease severity. Research in clinical settings shows that administering neutralizing antibodies early on leads to better patient results during SARS-CoV infection. This method provides a precise means to fight the virus while minimizing the risk of side effects.
Therapeutic Strategies Exploitation
People with higher infection risks gain passive protection from preventive anti-SARS-CoV antibody treatment. Individuals receive pre-formed antibodies through prophylactic administration to prevent infection prior to viral exposure. Healthcare workers and immunocompromised patients who experience greater exposure risks experience substantial benefits from preventive antibody treatments. The implemented strategy delivers fast protection that aids in controlling outbreaks while reducing virus transmission rates.
Creative Biolabs provides researchers with advanced tools for fighting SARS-CoV to drive scientific advancements. Our antibody portfolio delivers extensive targeting options for essential viral proteins. Our antibodies work effectively across multiple applications like ELISA and IF, as well as IHC.
REFERENCES
- Santos, Igor de Andrade, et al. "Antivirals against coronaviruses: candidate drugs for SARS-CoV-2 treatment?" Frontiers in microbiology 11 (2020): 1818. https://doi.org/10.3389/fmicb.2020.01818
- Fakhri, Sajad, et al. "Targeting multiple signal transduction pathways of SARS-CoV-2: Approaches to COVID-19 therapeutic candidates." Molecules 26.10 (2021): 2917. https://doi.org/10.3390/molecules26102917
- Distributed under Open Access license CC BY 4.0, without modification.
